Related Experiment Video
Updated: Jun 14, 2025
Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
Published on: April 4, 2022
Emerging Therapeutic Targets for Acute Coronary Syndromes: Novel Advancements and Future Directions
Andreas Mitsis1, Michael Myrianthefs1, Stefanos Sokratous1
1Cardiology Department, Nicosia General Hospital, State Health Services Organization, Nicosia 2029, Cyprus.
Abstract:
Acute coronary syndrome (ACS) remains a major cause of morbidity and mortality worldwide, requiring ongoing efforts to identify novel therapeutic targets to improve patient outcomes. This manuscript reviews promising therapeutic targets for ACS identified through preclinical research, including novel antiplatelet agents, anti-inflammatory drugs, and agents targeting plaque stabilization. Preclinical studies have expounded these agents' efficacy and safety profiles in mitigating key pathophysiological processes underlying ACS, such as platelet activation, inflammation, and plaque instability. Furthermore, ongoing clinical trials are evaluating the efficacy and safety of these agents in ACS patients, with potential implications for optimizing ACS management. Challenges associated with translating preclinical findings into clinical practice, including patient heterogeneity and trial design considerations, are also discussed. Overall, the exploration of emerging therapeutic targets offers promising avenues for advancing ACS treatment strategies and improving patient outcomes.
Insights
Novel therapies targeting platelet activation, inflammation, and plaque stabilization show promise for acute coronary syndrome (ACS). Ongoing trials aim to translate preclinical findings into improved patient outcomes for this widespread condition.
Area of Science:
- Cardiology
- Pharmacology
- Translational Medicine
Background:
- Acute coronary syndrome (ACS) is a leading cause of death globally.
- Current treatments require enhancement through novel therapeutic strategies.
- Identifying new targets is crucial for improving patient survival and reducing morbidity.
Purpose of the Study:
- To review emerging therapeutic targets for acute coronary syndrome (ACS) based on preclinical research.
- To discuss the potential clinical implications of these novel agents.
- To highlight challenges in translating preclinical findings to clinical practice.
Main Methods:
- Review of preclinical studies on novel antiplatelet agents, anti-inflammatory drugs, and plaque-stabilizing agents.
- Analysis of efficacy and safety data from these preclinical investigations.
- Consideration of ongoing clinical trials evaluating these agents in ACS patients.
Main Results:
- Preclinical data demonstrate efficacy of novel agents in addressing key ACS pathologies like platelet activation and inflammation.
- Agents targeting plaque stabilization show potential in preclinical models.
- Clinical trials are underway to validate these findings in human subjects.
Conclusions:
- Emerging therapeutic targets show significant promise for advancing acute coronary syndrome (ACS) treatment.
- Successful translation of these agents could optimize ACS management and improve patient outcomes.
- Addressing challenges in clinical translation is key to realizing the full potential of these novel therapies.
More Related Videos
07:40Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
Published on: May 26, 2023
18:11A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
Published on: December 28, 2012
Related Concept Videos
01:27Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:16Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...